Table 3.
Reductions in Dlco and FEV1 Are Associated With Increased COPD Exacerbations
| Outcome | Dlco % Predicted |
FEV1 % Predicted |
||
|---|---|---|---|---|
| Rate Ratio (95% CI) | P Value | Rate Ratio (95% CI) | P Value | |
| Any exacerbations | 1.05 (0.97 to 1.12) | .231 | 1.22 (1.19 to 1.27) | < .001 |
| Moderate exacerbations | 1.01 (0.93 to 1.10) | .759 | 1.20 (1.16 to 1.27) | < .001 |
| Severe exacerbations | 1.14 (1.05 to 1.20) | < .001 | 1.27 (1.20 to 1.33) | < .001 |
Associations are per 10% decrease in percent predicted Dlco or percent predicted FEV1. Exacerbation models (N = 1,806) include age, sex, ethnicity, BMI categories, education, pack-years, smoking status, diabetes status, anemia status, congestive heart failure status, sleep apnea status, emphysema as a categorical variable (missing data, ≤ 5% LAA-950, and > 5% LAA-950), percent predicted Dlco, and percent predicted FEV1. Any exacerbation refers to all episodes requiring antibiotics or steroids, moderate refers to only those episodes not resulting in an ED visit or hospitalization, and severe refers to those requiring an ED visit or hospitalization. See Table 1 legend for expansion of abbreviations.